You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東誠藥業(002675.SZ):下屬公司獲得68Ga-LNC1007注射液的藥品臨牀試驗授權通知書
格隆匯 04-10 16:29

格隆匯4月10日丨東誠藥業(002675.SZ)公佈,2024年4月9日,煙台東誠藥業集團股份有限公司下屬公司LNC PHARMA PTE.LTD.收到新加坡衞生科學局(簡稱“HSA”)核准簽發的關於68Ga-LNC1007注射液的藥品臨牀試驗授權通知書,將於近期在新加坡開展I期臨牀試驗。

公司在研產品 68Ga-LNC1007注射液是一種新型雙靶點放射性體內診斷藥物,同時靶向成纖維細胞活化蛋白(Fibroblast Activation Protein,簡稱“FAP”)和整合素αvβ3(Integrinαvβ3,簡稱“αvβ3”),擬用於診斷FAP和αvβ3陽性的成人實體瘤。

目前國內外暫無同產品上市,亦無相關銷售數據。截至目前,68Ga-LNC1007注射液相關項目累計已投入研發費用約737.94萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account